Poul Strange
Medical Director and President @Integrated Medical Development
Signup · Get unlimited contacts
WORK HISTORY
Medical Director and President @Integrated Medical Development
US
After 15 years in pharma holding positions in molecular pharmacology, animal pharmacology, clinical pharmacology, clinical development and finally medical affairs, the last 16 years have been spent providing clinical development guidance for the biotech, device and pharma industries while in parallel building a clinical CRO Integrated Medical Development (IMD). The combination has resulted in numerous new medical product approvals.IMD’s strengths are clinical trial design and simulation, statistical analysis and all data collection in clinical trials utilizing a proprietary suite of integrated software platforms. As IMD’s controls the software we can adapt it to solve unique clinical development challenges including monitoring insulin dose algorithm adherence and hypoglycemia induction bringing the critical component to secure regulatory clearance. After pioneering continuous glucose monitoring (CGM) to facilitate product development many years ago, recent developments has brought IMD back to this space. Specialties: Drug and device development with everything it takes from the lab to the formulary placement. Study design optimization through simulations.
EDUCATION
Copenhagen Business School
HD, International Trade
Københavns Universitet - University of Copenhagen
PhD, Immunology
SKILLS
ABOUT POUL STRANGE
After 15 years in pharma holding positions in molecular pharmacology, animal pharmacology, clinical pharmacology, clinical development and finally medical affairs, the last 16 years have been spent providing clinical development guidance for the biotech, device and pharma industries while in parallel building a clinical CRO Integrated Medical Development (IMD). The combination has resulted in numerous new medical product approvals.IMD’s strengths are clinical trial design and simulation, statistical analysis and all data collection in clinical trials utilizing a proprietary suite of integrated software platforms. As IMD’s controls the software we can adapt it to solve unique clinical development challenges including monitoring insulin dose algorithm adherence and hypoglycemia induction bringing the critical component to secure regulatory clearance. After pioneering continuous glucose monitoring (CGM) to facilitate product development many years ago, recent developments has brought IMD back to this space. Specialties: Drug and device development with everything it takes from the lab to the formulary placement. Study design optimization through simulations.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.